Perlmutter Cancer Center at NYU Langone Health
@Perlmutter_CC
We combine visionary thinking and compassionate care with the science of treating cancer. An NCI-designated Comprehensive Cancer Center, part of @NYULangone
Engineers at @nyutandon & @Perlmutter_CC have published a review on human cancer-on-chip platforms used to model the tumor microenvironment. They also explore what’s next for developing next-gen systems to advance precision cancer medicine. Read more: doi.org/10.1039/D4LC01…
Starting now at @OncLive #BTGLung2025, this awesome panel on #EGFR w/ @JuliaRotow, @AnaVManana, @LeXiuning, @ElaineShumMD + @JSabari! Perfect timing w/ +OS signal from FLAURA2!
I want to also give credit to phenomenal @nyugrossman MS3 Felicia Pasadyn and @NYUImaging resident @SamPlattMD who both took ownership of their projects and have first-author #rsna2025 accepted abstracts as a result.
This year at #RSNA2025 our team at @NYUImaging @cai2r is presenting on our breast multimodal model (MG/US/MRI) with external validation, and its use in high-risk women for cancer detection and long-term risk prediction. We also have a presentation on our exciting new…
Great article with our chief medical officer and hematologist, Dr. Jonathan Gerber ⤵️
IHC Testing May Enable Expedited Identification of TP53-Mutant MDS and AML @ShyamPatelMDPhD @nyugrossman #mpnsm #leusm #oncology #OncClub onclive.com/view/ihc-testi…
Check out the top 5 OncLive videos under 5 minutes right here, including insights from @JaniceM10, @TaliAzen, and others! See more here: hubs.li/Q03x8tKd0
Ever wondered why patients on #Belzutifan develop hypoxia? In our latest review led by senior fellow John Kucharczyk (@Perlmutter_CC @NYULISOM_HemOnc ), we unravel the mechanism behind this unique side effect and offer practical monitoring recommendations.
Welcoming Dr. John P. Leonard as chief of the Division of Hematology & Medical Oncology and director of the Center for Blood Cancers at @Perlmutter_CC! A global leader in lymphoma care, he brings decades of research and clinical expertise. Learn more: bit.ly/46eRupF
Read more in @natBME by Chao Ma, Huishu Wang, @LunanLiu, @shadab_kazmi, @xfang01, @iannisaifantis1, @SabaGhassemi et al. of @PennPathLabMed, @NYUGSOM_Path, and @Perlmutter_CC. nature.com/articles/s4155…
Coming up at 2pm East, join @DrMarcSiegel as he talks with @NYULangoneLI's Dr. Douglas Marks from @Perlmutter_CC about advances in #breastcancer treatments & lifestyle research. Tune in LIVE here: sxm.app.link/DoctorRadio
🎥@JaniceM10 of @Perlmutter_CC shares Phase II data on sarilumab + checkpoint blockade in unresectable melanoma. IL-6 inhibition may boost efficacy & reduce toxicity across tumor types. From #ASCO25: ➡️ow.ly/MS7H50WsxCx⬅️ @ASCO #Melsm #Skcsm #ImmunoOnc #CTSM #Trial…
Thanks Dr. Parsa Mirhaji (@pmirhaji), middle, from @Perlmutter_CC @nyuniversity for presenting "Patient Screening and Clinical Trials Matching Using #LLMs" today @WCMEnglanderIPM with Adil Ahmed, right, #MachineLearning Engineer from @EinsteinDeptMed, with @ElementoLab, left.
Treatment Algorithm series: Diffuse Large B-Cell Lymphoma DLBCL w/ @JohnPLeonardMD ✅ Work-up & 1L Rx ✅ CAR-T ✅ R/R: BiTEs/More chemo Full discussion: - oncbrothers.com/dlbcl-algo-2025 - Also on the “Oncology Brothers” podcast #HemeTwitter #OncTwitter #lymsm @OncUpdates
Sarilumab Plus Ipilimumab, Nivolumab, and Relatlimab Displays High Response Rate in Unresectable Melanoma #oncology #melanoma @JaniceM10 @Perlmutter_CC hubs.li/Q03xhxb50
@Perlmutter_CC Chief Fellow Dr. Morgan Simons presenting our analysis of neoadjuvant therapy use from the National Cancer Database in Naples, Italy. There is a very distinguished crowd in attendance. Proud mentor here.
Various trials within the small cell #LungCancer space were brought to light following recent data, impacting how patients will be treated in the future. @Jsabari @Perlmutter_CC @RoswellPark hubs.li/Q03vJjbQ0
We hope you can join us next Thursday for our @WCMEnglanderIPM #PrecisionMedicine Seminar with Dr. Parsa Mirhaji (@pmirhaji) from @Perlmutter_CC @nyuniversity!
Don't miss the next @WCMEnglanderIPM #PrecisionMedicine Seminar with Dr. Parsa Mirhaji (@pmirhaji) from @Perlmutter_CC @nyuniversity, "Patient Screening and Clinical Trials Matching Using #LLMs" on July 17th at noon!
Child walks again after receiving experimental treatment for rare genetic condition statnews.com/2025/07/09/nyu… Incredible study in @Nature from my soon to be next door lab neighbor @MichaelPacold @nyulangone @Perlmutter_CC
Sharing some personal news - excited for this next step! NYU Langone Names Chief of Division of Hematology & Medical Oncology & Director of the Center for Blood Cancers nyulangone.org/news/nyu-lango…
Huge thanks to our incredible Clinical Trials team for showcasing 9 poster presentations at @AACI_Cancer's Clinical Research Innovation (#CRI2025) annual meeting last week, highlighting innovative strategies to advance effective and efficient cancer research. 👏
Don't miss the next @WCMEnglanderIPM #PrecisionMedicine Seminar with Dr. Parsa Mirhaji (@pmirhaji) from @Perlmutter_CC @nyuniversity, "Patient Screening and Clinical Trials Matching Using #LLMs" on July 17th at noon!